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Abstract
Background: Fully human monoclonal antibodies directed against specific pathogens have a high therapeutic potential,
but are difficult to generate.
Methodology/Principal Findings: Memory B cells were immortalized by expressing an inducible active mutant of the
transcription factor Signal Transducer and Activator of Transcription 5 (STAT5). Active STAT5 inhibits the differentiation of B
cells while increasing their replicative life span. We obtained cloned B cell lines, which produced antibodies in the presence
of interleukin 21 after turning off STAT5. We used this method to obtain monoclonal antibodies against the model antigen
tetanus toxin.
Conclusions/Significance: Here we describe a novel and relatively simple method of immortalizing antigen-specific human
B cells for isolation of human monoclonal antibodies. These results show that STAT5 overexpression can be employed to
isolate antigen specific antibodies from human memory B cells.
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Introduction
In general, vaccination is a safe and efficient way to protect the
human body against specific pathogens. However, vaccination is
only applicable as a preventive measure, and development of new
vaccines is a slow and expensive process. As an alternative, the use
of sera enriched for pathogen-specific antibodies has been
suggested [1,2]. Treatment with pathogen-specific antibodies
could then be applied in a prophylactic as well as in a therapeutic
setting. However, non-human derived sera often provoke an
immune response, thereby limiting the maximum number of
treatments. Other possible caveats are the fact that it is difficult to
obtain large amounts of sera of the same quality, and the risk of
contamination with pathogens, in particular with viruses such as
but not limited to Human Immunodeficiency Virus (HIV) and
Hepatitis C Virus (HCV).
An alternative is the use of monoclonal antibodies [3]. Mouse
monoclonal antibodies such as OKT3 have been used to treat
humans but with limited success due to the immune response these
antibodies provoked. An alterative approach could be the use of
fully human antibodies. For this, novel technologies have been
developed, including humanization of mouse antibodies, phage
display of human B cell libraries, single cell PCR technologies and
the creation of mice that express human immunoglobulin genes
[4,5,6,7,8,9].
All of these technologies have resulted in clinical relevant
antibodies but most methods do not directly tap the potential of
the human immune system. Indeed, the human immune system
itself can safely be assumed to be the best in generating highly
efficacious antibodies and these antibodies are most likely superior
to those generated from mice or using phage display. In addition,
such antibodies may have a better safety profile than antibodies
derived from mice. Novel technologies to obtain monoclonal
antibodies from human B cells include EBV transformation of
antibody-producing B cells activated by TLR9-agonists [10,11]
and single cell PCR to obtain immunoglobulin genes from
individual ex vivo isolated B cells [12,13]. We have previously
shown that with forced expression of BCL-6 in human B cells
stable human monoclonal antibody secreting cell lines can be
produced [14,15]. We moved on to describe that ectopic
expression of a constitutively active mutant of the transcription
factor Signal Transducer of Transcription 5 (STAT5) in human
memory B cells resulted in a differentiation block of activated B
cells, preventing them to mature into plasma cells. STAT5
transduced cells resemble activated germinal center centrocytes
and show enhanced survival and expansion [16].
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e17189In the present paper we exploited this enhanced survival and
expansion of human memory B cells that express an active form of
STAT5 in order to obtain antigen specific immunoglobulin. We
established a series of cloned lines of human B cells that expressed
an inducible STAT5 construct. By turning off STAT5 the clones
regained their capacity to produce antibodies allowing identifica-
tion of clones that produced specific antibodies.
Results
STAT5bER
pos B cells preserve capacity to produce
immunoglobulins
Previously we have published that ectopic expression of active
STAT5 mutants in human primary B cells results in a block in B
cell differentiation and that these cells show enhanced survival and
expansion [16]. We extended these findings by showing that
constitutive activation of STAT5 in B cells led to loss of antibody
surface expression when cultures were maintained for more than 6
weeks in the presence of IL-2 and IL-4 [17]. We then investigated
whether we could exploit the immortalizing capacity of active
STAT5 mutants in order to obtain human monoclonal B cell lines,
which secrete antigen specific antibodies. For this, peripheral
blood CD27
pos memory B cells were cultured in the presence of
irradiated CD40-Ligand expressing L cells (CD40L-L cells) and
interleukin (IL)-21 prior to retroviral transduction with constitu-
tively activated (CA) STAT5b (CA-STAT5b). Pre-stimulation with
IL-21 induced strong proliferation, which resulted in transduction
efficiencies of 40 to 80% [15,18]. Following transduction, in-active
CA-STAT5b is expressed as a chimera with the hormone-binding
portion of the Estrogen Receptor (ER) (CA-STAT5bER) [16],
thereby STAT5b is expressed in the cytoplasm complexed by
heat-shock proteins. Incubation with tamoxifen (4-HT) leads to
dissociation of the heat shock proteins from constitutively active
STAT5bER, which results in receptor dimerization and subse-
quent translocation to the nucleus where it initiates STAT5
specific transcription [16,19]. First we studied the effect of STAT5
transduced cells cultured with IL-2, IL-4 and tamoxifen or with
IL-21 and tamoxifen. IL-2 and IL-4 induce proliferation of human
primary B cells similar to IL-21 but IL-21 has been shown to also
induce strong differentiation of B cells [20,21,22,23,24,25]. The
secreted immunoglobulin levels in the supernatant of the CA-
STAT5bER B cells were measured over time. Around 3 to 4
weeks after transduction the level of secreted IgG started to
decrease for the tamoxifen/IL-2 plus IL-4 and tamoxifen/IL-21
cultured cells (Figure 1a). We also determined the long-term effect
of constitutively active STAT5 expression on IgM secretion. IgM
expressing peripheral blood B cells were transduced with CA-
STAT5bER and cultured with tamoxifen, IL-2 and IL-4. Similar
to the IgG secretion levels, IgM secretion disappeared in CA-
STAT5bER B cells after prolonged culture (Figure 1b).
The decline in immunoglobulin secretion corresponded with a
decline in surface immunoglobulin expression [17]. This shows
that with time, constitutive expression of STAT5 in human B cells
leads to diminished expression and secretion of immunoglobulins.
We questioned whether these effects could be reversed by de-
activation of constitutively active STAT5 through removal of
tamoxifen from the culture. We cultured the cells with tamoxifen,
IL-2 and IL-4 for weeks to months until immunoglobulin
production had vanished and then removed tamoxifen from the
culture. In these cultures, when treated with IL-2 and IL-4
immunoglobulin secretion remained low or absent (Figure 2), but
when they were treated with IL-21, IgM or IgG immunoglobulin
secretion resumed (Figure 2 and Figure S1). The immunoglobulin
secretion lasted for about 7 days (Figure S2). After approximately
14 days antibody production came to an end and the transduced B
cells died [16]. It has been shown previously that IL-21 induces
differentiation of B cells into plasma cells, but this was not
observed in our B cells when STAT5 was active [18,24,25].
Together these data support the idea that IL-21 (but not IL-2 in
combination with IL-4) induces strong plasma cell differentiation,
which can be prevented by activation of STAT5 [16,18,24,25].
Interestingly, our B cell lines maintained the capacity to secrete
Figure 1. STAT5bER immortalized memory B cells down regulate Ig secretion. A) IgG production in time from STAT5bER transduced
memory B cells cultured in the presences of CD40L, IL-2, IL-4 and tamoxifen (4HT) or CD40L, IL-21 and tamoxifen (4HT). Two representative donors
out of 10 donors are shown. B) IgM production of peripheral blood B cells transduced with CASTAT5b cultured in the presence of CD40L, IL-2 and IL-4
at day 8 and 65 after transduction. Depicted are data from two donors.
doi:10.1371/journal.pone.0017189.g001
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even after freeze thawing (Figure S3).
Establishment of cell lines from STAT5bER
pos memory B
cells
Next we determined whether we could obtain stable cell lines
from STAT5bER
pos memory B cells isolated from clonal density
cultures. For this we isolated CD27
pos memory B cells from the
peripheral blood of two different donors, cultured these cells with
CD40L-L cells plus IL-21 for 36 hrs, transduced them with
STAT5bER-IRES-GFP and subsequently cultured these cells with
CD40L-L cells, IL-2, IL-4 and tamoxifen. After seven days GFP
pos
B cells were plated out at a density of 1000, 100, 10 and 1 cell per
well using high speed cell sorting and cultured with CD40L-L cells,
IL-2, IL-4 and tamoxifen. Within two weeks multiple poly- and
monoclonal STAT5bER memory B cell clones expanded. The
frequency of outgrowth was 84%, 42%, 8% and 4% for the 1000,
100, 10 and 1 cell per well cultures respectively. These data show
that stable STAT5bER
pos memory B cell clones can be obtained
from clonal cultures.
Isolation of Tetanus Toxin (TT)-specific STAT5bER
pos B cell
lines
Since transduction of human B cells with STAT5bER can be
utilized to develop immunoglobulin producing B cells lines
cultured at clonal density, the next step was to determine whether
we could make antigen specific immunoglobulin producing B cells
lines. TT is produced by the gram-positive bacterium Clostridium
tetani. Infants are routinely vaccinated with a combination vaccine
against diphtheria, pertussis, tetanus, and poliomyelitis (DPTP)
[26]. As a consequence, most adults have memory B cells
specifically directed against TT in their blood that can be detected
using PE-conjugated recombinant TT C-Fragment (rTT.C)
(Figure S4) [15,27]. Using flow cytometry rTT.C
pos CD27
pos
memory B cells were isolated from the peripheral blood of healthy
donors and cultured on CD40L-L cells in the presence of IL-21.
After 36 hrs the cells were transduced with STAT5bER-IRES-
GFP and cultured again on CD40L-L cells, now in the presence of
IL-2, IL-4 and tamoxifen. Seven days after transduction the cells
were checked for TT binding (Figure 3a), GFP sorted and
maintained in microcultures of 1, 5 and 10 cells per well, again in
the presence of CD40L-L cells, IL-2, IL-4 and tamoxifen. Within
two weeks a number of rTT.C
pos STAT5bER
pos memory B cell
clones could be selected (Table 1) and expanded further. Next we
determined whether these rTT.C sorted cultures still had the
capacity to produce immunoglobulins. After removal of tamoxifen
from the cultures, rTT.C sorted STAT5bER
pos clones resumed
production of either IgM or IgG (Figure 3b and c). Next we
determined the antigen specificity of the rTT.C
pos STAT5bER
pos
memory B cell lines. The majority of clones expressing either IgM
(54%) or IgG (69%) were specific for TT as determined by IgM
and IgG specific TT ELISA (Figure 3d and e). Together these data
show that the immortalizing capacity of STAT5bER can be used
to obtain B cell lines with the capacity to secrete antigen specific
immunoglobulins.
It should be mentioned that we also found high numbers of IgA
expressing cells in our STAT5bER transduced memory B cell
populations, which indicates that these IgA expressing cells can be
transduced and maintained in culture like the IgG and IgM
expressing cells (Figure S5).
rTT.C sorted STAT5bER
pos clones are monoclonal and
have undergone somatic hypermutation
A crucial hallmark of memory B cells is that the cells have
undergone somatic hypermutation [28] and affinity maturation,
the mechanisms via which they become able to develop high
affinity antibodies. For this reason we determined the mutation
status of TT specific STAT5bER
pos memory B cell lines from one
donor (Figure 3d and e). Monoclonality of memory B cell lines that
were cultured at clonal density (Table 1) could be confirmed by
VDJ sequencing per cell line, as only one VDJ sequence per cell
line was detected (Figure 4). From this one donor, we obtained
three independent immunoglobulin sequences – one IgG and two
IgM sequences (Figure 4). Interestingly, one IgG and one IgM had
a similar basic pattern of somatic hypermutation, with the IgM
sequence containing 6 additional mutations, one of which led to an
amino acid change. This suggests that these memory B cells arose
from the same clone, and that the IgM clones had undergone
additional somatic hypermutation and affinity maturation.
Discussion
The results presented in this study demonstrate that the
immortalizing capacity of an inducible active STAT5 mutant
can be used to obtain human, antigen-specific, monoclonal B cell
lines, which have the capacity to undergo plasma cell differenti-
ation. After turning off STAT5 these cells can then be induced to
secrete immunoglobulins. By making use of memory B cells
isolated from healthy donors we could screen for B cells that have
been positively selected for high affinity against a specific antigen.
Recently we published evidence that continued activation of
STAT5 plays a role in the lymphomagenesis of classical Hodgkin
Lymphoma [17]. We showed that long-term culture of primary B
cells expressing constitutive active STAT5 mutants eventually led
to a phenotype closely resembling classical Hodgkin Lymphoma
cells, including the loss of immunoglobulin expression and other B
cell specific markers as CD20 [29,30,31]. The absence of
Figure 2. IL-21 induces enhanced antibody secretion by CA-
STAT5bER immortalized memory B cells. Polyclonal CA-STAT5bER
transduced memory B cells were deprived from tamoxifen (4HT) for 7
days and cultured with IL-2 and IL-4 or with IL-21 before IgG secretion
was determined. Data shown are from one representative donor out of
5 donors. In all cultures (in culture for at least 2 months) transduced B
cells had lost surface immunoglobulin expression.
doi:10.1371/journal.pone.0017189.g002
Isolation of Antibodies from Human B Cells
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Hodgkin lymphoma [32]. In approximately 25% of the cases
mutations leading to a crippled immunoglobulin expression can be
found [32,33]. However, in the majority of the cases no crippled
mutations can be found and epigenetic events on the promoter
region of the immunoglobulin heavy chain have been proposed as
an alternative explanation for the absence of immunoglobulin
expression by Hodgkin Lymphoma cells [28].
In this paper we show that inactivation of STAT5 (by removing
tamoxifen from the cultures) in the presence of IL-21 results in re-
appearance of immunoglobulin expression, although levels are still
relatively low compared to levels normally described for ex vivo
derived plasma cells. This suggests that the loss of immunoglobulin
expression by primary B cells transduced with STAT5bER is
dependent on activation of STAT5. We have found previously
that activation of STAT5 in primary B cells inhibits the expression
of Blimp-1. Blimp-1 is a transcription factor crucial for plasma cell
differentiation [16,34,35], and we here postulate that inactivation
of STAT5 in our cell cultures leads to re-activation of Blimp-1 and
subsequent differentiation of these cells into antibody secreting
plasma cells.
The STAT5b-ER transduced B cells only secrete antibody
when STAT5b-ER is inactivated and in the presence of IL-21. IL-
21 induces proliferation and plasma cell differentiation in B cells,
both in mice as well as in humans [23,24,25,36,37]. This occurs at
least partly through upregulation of Blimp-1 by STAT3 activation
Figure 3. Generation of monoclonal rTT.C
pos STAT5bER
pos memory B cell lines. A) staining for rTT.C and CD27 on CD19 gated, CA-STAT5ER
transduced peripheral blood B cells that were first sorted for rTT.C and CD27 before being transduced with STAT5bER. B) IgM and C) IgG ELISA
performed on supernatants derived from the rTT.C
pos STAT5bER
pos memory B cell clones cultured with IL-2, IL-4 plus tamoxifen (4HT) or with IL-21
alone. Fold increase in secretion is shown. D) The frequency of rTT.C
pos clones within the IgM secreting clones (6 out of 11) and E) of IgG secreting
clones (11 out of 16).
doi:10.1371/journal.pone.0017189.g003
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STAT3 induced differentiation but the activation of STAT5 by
IL-21 is only transient (30 hrs) compared to STAT3 (days).
Stimulation with IL-2 and IL-4 did not lead to antibody secretion,
which is expected since both cytokines induce proliferation but do
not plasma cell differentiation of B cells [16,40,41,42].
The extended lifespan induced by forced expression of inducible
STAT5 mutants described in this paper provides a tool to expand
in vitro cultured single human memory B cells to obtain
monoclonal cell lines. However these cell lines do not express
any immunoglobulins when the inducible active STAT5 mutant is
‘‘on’’. By subsequently inactivating STAT5 the cells regained the
capacity to produce immunoglobulin offering an opportunity to
screen the clones for secretion of specific antibodies. It should be
noted that antigen specificity was not selected for by a functional
assay. Instead, we used a binding assay (ELISA) to screen for anti-
tetanus toxoid specific antibodies. It has been described previously
however that TT specific antibodies selected through binding
assays (ELISA) are functional as shown in a Toxin Binding
Inhibition test (ToBI) and in in vivo TT challenge models in mice
[43][44]. Following selection of the antigen-specific clones the
immunoglobulin genes can be retrieved from the clones. An
obvious next step would be to scale up the production of
antibodies through recombinant expression of the identified
immunoglobulin genes in suitable cell lines. These recombinant
antibody proteins can then be tested for other effector functions
like antigen dependent cellular cytotoxicity (ADCC), complement
activation or in vivo in mice for toxin inactivation properties.
The relevance of the technology we present here is that it can be
used to obtain monoclonal antibodies that are antigen specific, even
when present only in low frequencies in humans. Indeed, direct
isolation from the blood of influenza virus-specific B cells with a
highly restricted B cell receptor repertoire has been described
recently. However, healthy volunteers in this study had received
booster vaccination against Influenza, inducing high percentages of
antibody secreting plasma cells in the peripheral blood of these
individuals [12]. Indeed, such abundance of antigen-specific plasma
cells is unique. Much more often the frequency of antigen specific
memory B cells is low, for example in cases where appropriate
vaccines to induce such overt antibody response are lacking. In
those instances the method described here may be applied to isolate
human antigen specific monoclonal antibodies.
Materials and Methods
Ethics Statement
The use of human materials was approved by the Medical
Ethical Committee of the Academic Medical Center of the
University of Amsterdam (project MEC 07/248) and was
contingent on written informed consent.
B cell isolation
B cells were obtained from buffy coats prepared from the
peripheral blood of adults (Sanquin, Amsterdam, Netherlands) by
Ficoll separation and CD19 MACS microbeads as described by the
manufacturer (Miltenyi Biotech). CD19 MACS-selected B cells were
subsequent sorted for CD3
negCD19
posCD27
pos,C D 3
negCD19
pos
CD27
possIgG
pos or CD3
negCD19
posCD27
pos TT
pos.
Flow cytometry
The following mAbs against the human molecules CD3 (SK7),
CD19 (SJ25C1), IgG (G18-145) (BD-Pharmingen, San Diego,
CA), CD27 (O323; eBioscience) and IgA (F(ab)2, DAKO), were
directly labeled with either fluoroscein isothiocyanate (FITC),
phycoerythrin (PE), phycoerythrin cyanine 5, (PE-Cy5), allophy-
cocyanin (APC), phycoerythrin-indotricarbocyanine (PE-Cy7),
phycoerythrin-cyanine 7 (PC7) or allophycocyanin-indotricarbo-
cyanine (APC-Cy7). Recombinant TT C-fragment was purchased
from Boehringer Mannheim (Mannhein, Germany) and conju-
gated to PE (Cyanotech Corporation, Kaila-kona, HI) as
previously described [27]. Stained cells were sorted using a
FACSAria (BD) and analyzed using a LSR-II (BD) and flow
cytometry data were processed with FlowJo computer software
(Treestar, Ashland, OR).
Retroviral transduction
The STAT5bER retroviral construct has been described
previously [16]. In brief, cDNA encoding STAT5bER was
expressed in the Lazarus (LZRS) vector upstream to a internal
ribosomal entry site (IRES) and a marker gene (a signaling-
Table 1. Limiting dilution culture of 100% GFP
pos TT-specific
B cells.
donor Number of positive clones from 96 wells
Total # from 1 c/w from 5 c/w from 10 c/w
A 12/96 2 10 N.D.
B 14/96 0 7 7
C 10/96 10 0 0
D 11/96 1 3 7
Indicated is the total number of clones isolated and at which cell density they
were seeded. One 96 well plate was used for each condition (1, 5 or 10 cell per
well). Wells contained 2500 CD40L-expressing L cells, IL-2 and IL-4. J to K of
the medium was replaced twice a week with fresh cytokines and 5000 L cells.
N.D. is not determined.
doi:10.1371/journal.pone.0017189.t001
Figure 4. Schematic representation of IgVH consensus sequence of TT
pos STATbER
pos memory B cell clones; 5D1, 10E1 and 10B7.
The horizontal bar of each clone represents the sequenced region. The FR1 to CDR3 region was sequenced for clone 5D1 and for clones 10E1 and
10B7 region FR2 to CDR3 were sequenced. We were unable to obtain reliable sequence data of the FR1- CDR1 region of clone 1E10. The lollipop-
shaped symbols indicate nucleotide difference with germline configuration, except for the CDR3 region. The CDR3 region of 10E1 is compared to
5D1. Replacement and silent mutations are indicated by closed and open circles, respectively.
doi:10.1371/journal.pone.0017189.g004
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Raphael Hospital, Milan, Italy or GFP) that allow independent
translation of the products of both genes in the transduced target
cells. Retroviral production by Phoenix packaging cells were
performed as described earlier [16]. B cells were transduced with
retroviruses after activation on CD40L-L cells in the presence of
recombinant mouse IL-21 (25 ng/ml; R&D systems) for 36 hrs.
After the transductions, cells were cultured in the presence of IL-2
and IL-4 (R&D systems).
Cell culture
B cells (2610
5) were co-cultured on c-irradiated (100 Gy) mouse
L cell fibroblasts stably expressing CD40L (CD40L-L cells, 10
5
well) and recombinant human IL-2, IL-4 or IL-21. Cells were
routinely tested by PCR for the presence of mycoplasma and EBV
(data not shown).
ELISA
Plates were coated with anti-human IgG (Dako) at 5 mg/ml in
PBS or Tetanus vaccine (Dutch vaccine institute, The Nether-
lands) diluted 1:10 for 1 hr at 37uC or o/n at 4uC and washed in
ELISA wash buffer (PBS, 0.5% Tween-20). 4% milk in PBS was
used as blocking agent, before serial dilution of cell culture
supernatants and enzyme-conjugated detection Abs were added
(dilutions 1:2500 for HRP-conjugated anti-IgG (Jackson Immu-
noResearch Laboratories) and 1:250 for AP conjugated anti-IgG
(DAKO)). TMB substrate/stop solution (Biosource) or Alkaline
Phosphatase Substrate (Sigma-Aldrich) was used for development
of the ELISAs. To detect Tetanus Toxin we used the ELISA
Ridascreen Tetanus (r-biopharm AG, Darmstadt, Germany).
Somatic hyper mutation analysis
Total RNA was isolated from approximately 5610
5 B cells with
Trizol (Invitrogen). cDNA was generated and subjected to PCR to
produce heavy chain fragments using 1 U AmpliTaq Gold DNA
polymerase (Applied Biosystems Inc.). PCR products were run on
agarose gels, purified and cloned into the pCR2.1 TA cloning
vector according to manufacturers’ recommendations (Invitrogen).
Sequence analysis was performed using BigDye Terminator
chemistry (Applied Biosystems Inc.) and Vector-NTI software
(Invitrogen). Consensus sequences were determined with Codon
code (CodonCode Corporation).
Supporting Information
Figure S1 IL-21 induced Ig secretion in STAT5bER
immortalized memory B cell cultures. A) STAT5bER
transduced polyclonal memory B cells were cultured in the
absence of tamoxifen (4HT) and with IL-2 and IL-4 or IL-21. IgG
secretion was determined at day 7. Data from two representative
donors out of 5 donors is shown. B) STAT5bER transduced
monoclonal memory B cell lines were cultured in the absence of
tamoxifen (4HT) and with IL-2 and IL-4 or IL-21. IgG secretion
was determined on day 7. Data from two representative cell
cultures is shown. All B cells in these cultures had lost surface
immunoglobulin expression and were in culture for at least 2
months.
(TIF)
Figure S2 IgG and IgM secretion in time after removal
of tamoxifen (4HT). IgG and IgM secretion was determined in
cells cultured with CD40L and IL-21 for 7 days and for 14 days.
Days 0 indicates the day when the culture conditions were
changed from CD40L, IL-2, IL-4 plus tamoxifen (4HT) to CD40L
and IL-21. The black and grey bars represents two different
donors.
(TIF)
Figure S3 IgG and IgM expression in long term
cultures. Multiple TT specific clones which were in culture for
more then 5 months and subsequent frozen. They were then
thawed and taken in culture again with CD40L, IL-2, IL-4 and
tamoxifen (4HT). When a stable culture was obtained, the cells
were cultured with CD40L and IL-21. An ELISA was performed
to determine IgG and IgM concentrations.
(TIF)
Figure S4 rTT.C staining on freshly isolated memory B
cells. Phycoerythrin (PE) labeled rTT.C was added to freshly
isolated B cells. Cells were subsequently sorted using flow
cytometry (FACSAria). Shown are the results of 5 different donors.
(TIF)
Figure S5 IgA and IgG expression on polyclonal CA-
STAT5b transduced and non-transduced B cells. A
polyclonal mixture of total CD27+ selected human memory B
cells from two donors were transduced with caSTAT5b-IRES-
NGFR and cultured for a maximum of two weeks before they
were frozen. After thawing cells were stained immediately for the
IgA and IgG isotype. Cells expressing NGFR indicates they were
transduced with CA-STAT5b.
(TIF)
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